

# UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2008

## AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,  
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 31.03.2008 (Reviewed)	Quarter ended 31.03.2007 (Reviewed)	Year ended 31.12.2007 (Audited)
<b>1 Sales</b>	2,203	2,265	9,317
<b>Less : Excise duty recovered</b>	134	136	582
<b>Net Sales</b>	2,169	2,129	8,735
<b>2 (a) Income from services rendered</b>	70	17	223
<b>(b) Interest and Dividend Income</b>	77	95	312
<b>(c) Other Income</b>	42	88	205
<b>3 Total Income (1+2)</b>	2,358	2,329	9,475
<b>4 Total Expenditure</b>			
<b>(a) (Increase)/Decrease in Stock in trade and work in progress</b>	114	(154)	(182)
<b>(b) Consumption of raw materials</b>	553	800	2,772
<b>(c) Purchase of Traded Goods</b>	411	388	1,635
<b>(d) Employees Cost</b>	283	210	1,037
<b>(e) Depreciation</b>	51	45	185

Particulars	Quarter ended 31.03.2008 (Reviewed)	Quarter ended 31.03.2007 (Reviewed)	Year ended 31.12.2007 (Audited)
<b>(f) Other Expenditure</b>	403	391	1,798
<b>(g) Total</b>	1,815	1,680	7,245
<b>5 Interest</b>	-	-	2
<b>6 Profit before tax (3) - (4+5)</b>	543	649	2,228
<b>7 Tax Expenses</b>			
- Current	202	190	726
- Deferred	(17)	17	14
- Fringe benefit tax	13	9	44
<b>8 Net Profit after tax (6-7)</b>	345	433	1,444
<b>9 Paid-up equity share capital (Face Value of Rs. 10 per Share)</b>	230	230	230
<b>10 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>			6,651
<b>11 Earnings Per Share (EPS) (Rs.)</b>	15.00	18.83	62.71
<b>12 Public Shareholding</b>			
- Number of Shares	9,120,955	9,120,955	9,120,955
- Percentage of Shareholding	39.60	39.60	39.60

### Notes:

- The above Results were approved by the Board of Directors of the Company at its Meeting held on April 23, 2008.
- The break up of Net Sales is as follows:

Rs Million

	Quarter ended March 31, 2008	Quarter ended March 31, 2007	Growth %
<b>Domestic Sales</b>	1,775	1,706	4.0%
<b>Export Sales</b>	394	423	-6.9%
<b>Total Sales</b>	<b>2,169</b>	<b>2,129</b>	<b>1.9%</b>

- The Company has a single business segment namely 'Pharmaceutical Business'.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended March 31, 2008.
- The Board of Directors had, at its Meeting held on February 21, 2008 recommended a Final Dividend of Rs. 12.50 per Equity Share of Rs. 10 for the year ended December, 31 2007. The dividend, if declared at the Annual General Meeting to be held on April 24, 2008 will be paid on or after April 25, 2008.
- Information on investor complaints is furnished below:

Pending as on January 1, 2008	Received during the quarter	Disposed of during the quarter	Pending as on March 31, 2008
Nil	2	2	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

**AVENTIS PHARMA LIMITED**  
**DR. SHAILESH AYYANGAR**  
**MANAGING DIRECTOR**